1378308-05-4

Basic information

• Product Name: (S)-benzyl (4-(3-methoxypyrrolidin-1-yl)cyclohexyl)carbamate
• Synonyms: (S)-benzyl (4-(3-methoxypyrrolidin-1-yl)cyclohexyl)carbamate
• CAS NO: 1378308-05-4
• Molecular Weight: 332.443
• Mol File: 1378308-05-4.mol

Chemical Properties

• CAS DataBase Reference: (S)-benzyl (4-(3-methoxypyrrolidin-1-yl)cyclohexyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-benzyl (4-(3-methoxypyrrolidin-1-yl)cyclohexyl)carbamate(1378308-05-4)
• EPA Substance Registry System: (S)-benzyl (4-(3-methoxypyrrolidin-1-yl)cyclohexyl)carbamate(1378308-05-4)

Safety Data

• Hazardous Substances Data: 1378308-05-4(Hazardous Substances Data)

Upstream product

• 16801-63-1 benzyl N-(4-oxocyclohexyl)carbamate 
• 120099-61-8 (S)-3-methoxy-pyrrolidine 

Downstream Products

• 1378308-06-5 (S)-4-(3-methoxypyrrolidin-1-yl)cyclohexanamine 

Relevant articles and documents

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.